<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78981">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975246</url>
  </required_header>
  <id_info>
    <org_study_id>1348.1</org_study_id>
    <nct_id>NCT01975246</nct_id>
  </id_info>
  <brief_title>Add-on to Micamlo BP Trial</brief_title>
  <official_title>An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double-blind, active-controlled, parallel-group
      comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg
      +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+
      amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the
      double-blind period in essential hypertensive patients who fail to respond adequately to
      telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a
      6-week open-label run-in period taking T80/A5 mg.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period</measure>
    <time_frame>baseline and week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period</measure>
    <time_frame>baseline and week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with DBP&lt;90 mmHg and SBP&lt;140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period</measure>
    <time_frame>baseline and week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan+amlodipine+HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan+amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + amlodipine</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>Telmisartan+amlodipine+HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide</intervention_name>
    <description>tablet</description>
    <arm_group_label>Telmisartan+amlodipine+HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + amlodipine</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>Telmisartan+amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo matching hydrochlorothiazide tablet</description>
    <arm_group_label>Telmisartan+amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs
             and mean seated diastolic blood pressure (DBP) must be &gt;=90 and &lt;=114 mmHg and mean
             seated systolic blood pressure (SBP) must be =&lt;200 mmHg

          -  Able to stop all current antihypertensive drugs (other than study medication) from
             Visit 1b through the end of the trial without risk to the patient based on the
             investigator's opinion

          -  Age 20 years or older

        Exclusion criteria:

          -  Patients with known or suspected secondary hypertension

          -  Patients with clinically relevant cardiac arrhythmia

          -  Congestive heart failure with New York Heart Association (NYHA) functional class
             III-IV

          -  Patients with recent cardiovascular events

          -  Patients with recent stroke events

          -  Patients with a history of sudden deterioration of renal function with angiotensin II
             receptor blockers or angiotensin converting enzyme inhibitors; or patients with
             post-renal transplant or post-nephrectomy

          -  Patients with hepatic and/or renal dysfunction

          -  Pre-menopausal women who are nursing or pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1348.1.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atsubetsu-ku,Sapporo,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Sapporo,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itoshima, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katsushika-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyose,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mihama-ku, Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagino-ku, Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriya, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-ku,Yokohama,Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakaide, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toshima-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
